Latest news

• Roche eyes September FDA verdict for triple NSCLC therapy

  Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.

• Roche faces biosimilar blitz in 2018

  year. Avastin (bevacizumab), Roche’s biggest-selling cancer drug, will imminently face some stiff competition in the EU from Amgen and Allergan’s recently licenced biosimilar Mvasi - which became the first

• Amgen and Allergan win first EU approval for Avastin biosimilar

  Amgen and Allergan win first EU approval for Avastin biosimilar. Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers. ... The approval was based on data showing Mvasi and beveacizumab are highly similar, with no clinically

• Mylan gets first biosimilar Herceptin OK from FDA

  cancer antibody after Amgen and Allergan got a green light for their Mvasi biosimilar of Roche’s Avastin (bevacizumab) in September.

• Amgen's Mvasi is first FDA-approved cancer biosimilar

  Amgen's Mvasi is first FDA-approved cancer biosimilar. Offers prospect of lower-cost alternative to Roche's Avastin. ... Mvasi reaches the market ahead of rival Avastin biosimilars from Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan that